Toxicity and outcome of children and adolescents participating in phase I/II trials of novel anticancer drugs: The Royal Marsden experience

Journal of Pediatric Hematology/Oncology

Volumn 36, Issue 3, 2014, Pages 218-223

  Morgenstern, Daniel A ^a   Hargrave, Darren ^b   Marshall, Lynley V ^a   Gatz, Susanne A ^a   Barone, Giuseppe ^a   Crowe, Tracey ^a   Pritchard Jones, Kathy ^c   Zacharoulis, Stergios ^a   Lancaster, Donna L ^a   Vaidya, Sucheta J ^a   Chisholm, Julia C ^a   Pearson, Andrew D J ^a,d   Moreno, Lucas ^a,d  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

childhood cancer; dose limiting toxicity; drug development; Phase I; phase II

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN TYROSINE KINASE INHIBITOR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM TUMOR; CHILD; CHILDHOOD CANCER; CHRONIC MYELOID LEUKEMIA; DRUG EFFICACY; DRUG SAFETY; EPENDYMOMA; EVENT FREE SURVIVAL; EWING SARCOMA; FEMALE; GLIOMA; HEALTH CARE ACCESS; HOSPITAL ADMISSION; HUMAN; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MEDULLOBLASTOMA; NEUROBLASTOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREATIC NEUROENDOCRINE TUMOR; PATIENT REFERRAL; PATIENT SELECTION; PATIENT TRANSPORT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RHABDOID TUMOR; RHABDOMYOSARCOMA; RISK BENEFIT ANALYSIS; SOLID TUMOR; TERATOMA; TREATMENT DURATION; TREATMENT RESPONSE; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; DRUG DESIGN; DRUG DISCOVERY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; INFANT; MALE; NEOPLASMS; PATIENT ADMISSION; PATIENT DROPOUTS; PATIENT SELECTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84897476173     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0000000000000003     Document Type: Article

References (25)

1. Smith MA, Seibel NL, Altekruse SF, et al. Outcomes for children and adolescents with cancer: Challenges for the twenty-first century. J Clin Oncol. 2010;28:2625-2634
2. Unguru Y. The successful integration of research and care: How pediatric oncology became the subspecialty in which research defines the standard of care. Pediatr Blood Cancer. 2011;56:1019-1025
3. Stiller C, Kroll M, Pritchard-Jones K. Population survival from childhood cancer in Britain during 1978-2005 by eras of entry to clinical trials. Ann Oncol. 2012;23:2464-2469
4. Pui CH, Gajjar AJ, Kane JR, et al. Challenging issues in pediatric oncology. Nat Rev Clin Oncol. 2011;8:540-549
5. Garrido-Laguna I, Hidalgo M, Kurzrock R. The inverted pyramid of biomarker-driven trials. Nat Rev Clin Oncol. 2011; 8:562-566
6. Yap TA, Sandhu SK, Workman P, et al. Envisioning the future of early anticancer drug development. Nat Rev Cancer. 2010; 10:514-523
7. International Conference on Harmonisation. ICH Harmonised Tripartite Guideline: Clinical investigation of medicinal products in the pediatric population, E11. 2000. Available at: Http://www.ich.org/fileadmin/Public-Web- Site/ICH-Products/Guidelines/Efficacy/E11/Step4/E11-Guideline.pdf. Accessed November 20, 2013
8. Boklan J. Little patients, losing patience: Pediatric cancer drug development. Mol Cancer Ther. 2006;5:1905-1908
9. Vassal G. Will children with cancer benefit from the new European Paediatric Medicines Regulation Eur J Cancer. 2009;45:1535-1546
10. Stiller C. Childhood Cancer in Britain: Incidence, Survival and Mortality. Oxford, UK: Oxford University Press; 2007
11. Moore AS, Kearns PR, Knapper S, et al. Novel therapies for children with acute myeloid leukaemia. Leukemia. 2013;27: 1451-1460
12. Fern L, Davies S, Eden T, et al. Rates of inclusion of teenagers and young adults in England into National Cancer Research Network clinical trials: Report from the National Cancer Research Institute (NCRI) Teenage and Young Adult Clinical Studies Development Group. Br J Cancer. 2008;99:1967-1974
13. Whelan JS, Fern LA. Poor accrual of teenagers and young adults into clinical trials in the UK. Lancet Oncol. 2008;9: 306-307
14. Kim A, Fox E, Warren K, et al. Characteristics and outcome of pediatric patients enrolled in phase I oncology trials. Oncologist. 2008;13:679-689
15. Lee DP, Skolnik JM, Adamson PC. Pediatric phase I trials in oncology: An analysis of study conduct efficiency. J Clin Oncol. 2005;23:8431-8441
16. Paoletti X, Geoerger B, Doz F, et al. A comparative analysis of paediatric dose-finding trials of molecularly targeted agent with adults? trials. Eur J Cancer. 2013;49:2392-2402
17. Estlin EJ, Cotteril S, Pratt CB, et al. Phase I trials in pediatric oncology: Perceptions of pediatricians from the United Kingdom Children?s Cancer Study Group and the Pediatric Oncology Group. J Clin Oncol. 2000;18:1900-1905
18. Yap TY, Yamokoski AD, Hizlan S, et al. Informed consent for pediatric phase 1 cancer trials: Physicians? perspectives. Cancer. 2010;116:3244-3250
19. Truong TH, Weeks JC, Cook EF, et al. Altruism among participants in cancer clinical trials. Clin Trials. 2011;8: 616-623
20. Bachelot T, Ray-Coquard I, Catimel G, et al. Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials. Ann Oncol. 2000; 11:151-156
21. Wheler J, Tsimberidou AM, Hong D, et al. Survival of patients in a Phase 1 Clinic: The M. D. Anderson Cancer Center experience. Cancer. 2009;115:1091-1099
22. Geoerger B, Aerts I, Casanova M, et al. A phase I/II study of LDE225, a smoothened (Smo) antagonist, in pediatric patients with recurrent medulloblastoma (MB) or other solid tumors. J Clin Oncol. 2012;30(suppl): Abstract 9519
23. Mosse YP, Lim MS, Voss SD, et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: A Children?s Oncology Group phase 1 consortium study. Lancet Oncol. 2013;14:472-480
24. Moreno L. ALK-targeted therapy for poor-prognosis childhood cancers. Lancet Oncol. 2013;14:439-440
25. Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367:107-114